Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2CNS 2NET 1

Conditions

Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Neuroblastoma 1

Interventions

lutetium Lu 177 dotatate 15Magnetic Resonance Spectroscopy 9Everolimus 8gallium Ga 68 dotatate 6lanreotide 4cabozantinib 4Temozolomide 4Specimen Handling 4Nivolumab 4Lutetium-177 4Lutetium 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4surufatinib 3olaparib 3copper dotatate CU-64 3Somatostatin 3Injections 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3Capecitabine 3pembrolizumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sunitinib 2Radiosurgery 2Octreotide 2Drug Therapy 2Cyclophosphamide 264Cu-DOTATATE 2zimberelimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × 3-fluorobenzylguanidine × NET × Clear all
NCT05069220 2024-03-01

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

Peking Union Medical College Hospital

Phase EARLY_PHASE1 Recruiting
150 enrolled
CNSEndocrineNET

Neuroblastoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡